Argenx Stock Drops 13% as Vyvgart Fails Phase 3 Sjögren's Trial — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Argenx said Thursday that Vyvgart didn't outperform placebo in a Phase 3 trial of patients with Sjögren's disease, a chronic autoimmune disorder.
- Argenx's stock slipped 13% Thursday morning following the announcement, a sharp reaction for one of the world's largest biotechs by market cap.
- The source calls the failure an unusual setback for Argenx, which has racked up a series of wins in autoimmune disorders en route to its current scale.
- Vyvgart is described in the source as Argenx's blockbuster, indicating the Sjögren's program was meant to extend the drug's reach beyond its already-approved autoimmune indications.
Why it matters: Argenx's 13% stock slide shows investors treated the Phase 3 miss as a serious blow — a rare stumble for a company that became one of the world's largest biotechs by market cap on the strength of Vyvgart's autoimmune wins. The Sjögren's failure knocks out a potential new use for the drug that drove that growth.
Ask SkimNews
